Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation

Y Dundar,1 A Bagust,2 R Dickson,1* S Dodd,3 J Green,4 A Haycox,2 R Hill,1 C McLeod1 and T Walley1

1 Liverpool Reviews and Implementation Group, University of Liverpool, UK
2 University of Liverpool Management School, UK
3 Centre for Medical Statistics and Health Evaluation, University of Liverpool, UK
4 Clatterbridge Centre for Oncology NHS Trust, Liverpool, UK

* Corresponding author

Executive summary

Health Technology Assessment 2007; Vol. 11: No. 1
How to obtain copies of this and other HTA Programme reports.

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it.

Contact details are as follows:

HTA Despatch

c/o Direct Mail Works Ltd
4 Oakwood Business Centre
Downley, HAVANT PO9 2NP, UK

Email: orders@hta.ac.uk
Tel: 02392 492 000
Fax: 02392 478 555
Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume.

Payment methods

Paying by cheque

If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address.

Paying by credit card

The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order

You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.
Objectives
The review aimed to assess the clinical effectiveness and cost-effectiveness of pemetrexed disodium in combination with cisplatin for the treatment of unresectable pleural mesothelioma in chemotherapy-naïve patients.

Background
Mesothelioma is a rare and rapidly progressive malignancy of the mesothelium. About 90% of cases involve the pleura (lining of the lungs) and the remainder affect the peritoneum (lining of the abdomen). Epidemiological studies indicate that incidence is increasing worldwide, and this increase is being attributed to previous exposure to asbestos.

Currently there is no gold-standard treatment for mesothelioma. Surgical treatment is an option for only a small minority of patients whose disease is at Stage I or II. Other treatment options may include chemotherapy, radiotherapy or supportive care.

Benefits of chemotherapy may include an improvement in symptoms and/or, occasionally, shrinkage in the size of the cancer. Various chemotherapy regimens (either as single agent or in combination) are used, including mitomycin, vinorelbine, platinum compounds, doxorubicin and antifolates.

Pemetrexed disodium, a new multitargeted antifolate, is the first and only chemotherapy agent that has been granted marketing approval for use in combination with cisplatin (administered with vitamin B_{12} and folic acid) for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.

Methods
The review was conducted following accepted guidelines for conducting systematic reviews including the identification of clinical and economic studies (1980 to May 2005), application of inclusion criteria, quality assessment of included studies and data extraction and analysis.

Inclusion criteria
Studies that compared pemetrexed disodium plus cisplatin with other cytotoxic agents or supportive care were considered for inclusion in the review. Data on the following outcome measures were considered: overall survival, toxicity, health-related quality of life, tumour response and progression-free survival.

Full economic evaluations that compared two or more options and considered both costs and consequences including cost-effectiveness, cost–utility analysis or cost–benefit analysis undertaken in the context of high-quality randomised controlled trials (RCTs) were considered for inclusion in the review.

An assessment was also carried out of the economic submission received from the manufacturer of pemetrexed comprising two sections, each employing a separate economic model. One of these models was then reformulated in order to carry out a separate exploration of economic performance.

Results
Clinical findings
One RCT comparing pemetrexed and cisplatin with cisplatin alone, and involving a total study population of 448 patients, met the inclusion criteria. The search failed to identify any other studies that compared the effectiveness of pemetrexed disodium and cisplatin with other commonly used alternatives such as vinorelbine, MVP (mitomycin C, vinblastine and cisplatin) or supportive care.

Pemetrexed in combination with cisplatin in this trial showed a 2.8-month gain in median survival compared with cisplatin alone in an intention-to-treat (ITT) population (12.1 and 9.3 months, respectively, \( p = 0.020 \), hazard ratio of 0.77). During the trial, increased reporting of severe toxicity in the pemetrexed arm led to a change in the protocol to add vitamin B_{12} and folic acid.
supplementation to therapy. For fully supplemented patients (n = 331) the hazard ratio for median survival in favour of pemetrexed plus cisplatin was also comparable (0.75), but of borderline significance between treatment arms (p = 0.051).

The trial inclusion criteria restricted recruitment to those with a Karnofsky performance status of 70 or greater (equivalent to ECOG/WHO 0 or 1 scales more widely used in the UK). Quality of life scores using the Lung Cancer Symptom Scale demonstrated significantly greater improvement for pain and dyspnoea for patients in the combination group compared with those in the cisplatin group.

In the ITT population, the incidence of serious toxicities with pemetrexed plus cisplatin was higher compared with cisplatin alone. However, the grade 3/4 toxicities of the combination arm, particularly leucopenia, neutropenia and diarrhoea, were found to be greatly improved by the addition of vitamin B12 and folic acid.

Economic evaluation
The existing published economic literature is very limited. Only one economic evaluation, available as a conference presentation, was identified for inclusion in the review.

The economic evaluation that we conducted (and that submitted by the manufacturer) suggests that pemetrexed is unlikely to be considered cost-effective at conventionally accepted thresholds in the UK for all patients. This is mainly due to the high cost of pemetrexed itself compared with cisplatin. These findings were better for some patient subgroups, e.g. especially for fully supplemented (FS) patients with good performance status (0/1) and advanced disease (AD). These findings seem robust.

Our estimated cost-effectiveness results were as follows:

- FS population: incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained = £59,600
- FS with AD population: ICER per QALY = £47,600
- FS with performance status 0/1 population: ICER per QALY = £49,800
- FS with performance status 0/1 and AD population: ICER per QALY = £36,700.

Implications for the NHS
Given the relatively small (albeit increasing) numbers of patients with mesothelioma, the overall budget impact to the NHS is likely to be in the range of £3–6 million. This assumes that only 25% of the malignant pleural mesothelioma (MPM) population are eligible for pemetrexed therapy. Most of this cost is the acquisition cost of pemetrexed itself. Whether pemetrexed plus cisplatin is to be recommended to the NHS requires careful consideration, given the extent by which the ICER exceeds conventional thresholds and the size of the NHS budget impact.

Conclusions
Mesothelioma will be a growing challenge for the NHS over the next 15–20 years, as patient numbers increase. Its poor prognosis is in part the result of late diagnosis but mainly due to the natural history of the tumour. This prognosis and the clinical course in which pain is often a prominent feature command our attention. That it is a condition brought on by occupational exposure may increase our sense of needing to respond to these patients.

Any new treatment promising palliation or increased life expectancy therefore may seem very attractive. In evaluating a new treatment, however, we need to consider what current best care is for such patients. Many patients receive only supportive care, in part related to the late stage of presentation. The concept of best supportive care is somewhat nebulous: it is almost synonymous with active symptom control and ideally it would consist of adequate pain relief managed by an experienced palliative care team who would also offer other forms of support to both patients and their families. However, this low-technology and low-cost approach is in practice not available to all patients. It would be sad if any new therapy attracted attention and resources away from this fundamental approach, which should be available to all patients.

The new therapy examined in this document demonstrates an extension of life expectancy and palliation, as measured by time to progression of disease and other end-points. The comparator in this trial was cisplatin, itself an unproven therapy in mesothelioma but justified on the grounds that there are no established regimens of chemotherapy proven to be of benefit in mesothelioma. This is strictly correct and the evidence presented is compelling, in several analyses, including those of the US Food and Drug Administration looking at fully supplemented patients at various stages of
disease. This is the largest trial yet conducted in mesothelioma, an impressive achievement, and will remain the best available evidence for some time to come. However, the absolute benefit obtained is small, and it needs to be weighed against the benefits of effective palliative care services. The limited benefit was also at the expense of considerable toxicity to patients. While the severe toxicities in early use were ameliorated by vitamin B12 and folic acid supplementation, even thereafter the incidence of toxicity was high.

The information on quality of life, which might be expected to capture the patient’s perception of the balance between benefit and toxicity and of effective palliative care, is limited at present and, for the economic evaluation presented here, it has been necessary to assume that data from other forms of lung cancer apply in this condition also.

Interestingly, the extension of life (2.8 months) was less than that previously suggested to be acceptable to patients with non-small cell lung cancer when weighed against the toxicity of a cisplatin-based chemotherapy regimen. Although the dose of cisplatin is important in determining toxicity, the extent to which patients would weigh the pemetrexed plus cisplatin regimen with its greater toxicity than cisplatin alone against a limited extension of life is unknown. It would seem that this is an issue of providing enough information about the risks and benefits of this therapy to allow them to make their choice.

The comparator in this study, cisplatin as monotherapy, is not the form of chemotherapy most widely used in the UK for mesothelioma. A large multicentre Phase III randomised trial of the most widely used treatments, mitomycin, vinblastine and cisplatin against vinorelbine and compared with active symptom control, is under way. Given that this trial also addresses the important question of whether any chemotherapy is better than supportive care, it would be unfortunate if this trial could not be carried on as a consequence of the pemetrexed plus cisplatin trial or a National Institute for Health and Clinical Excellence appraisal.

We believe that any decision to use pemetrexed plus cisplatin in an individual patient needs to be in full collaboration with that patient, against a background of high-quality palliative care services. The patient needs to be well informed of the benefits and toxicities of the regimen. Much more research is needed into the optimum chemotherapy for these patients and a clear definition of what constitutes best supportive care.

The economic evaluation conducted here and that of the manufacturer suggest that pemetrexed is not cost-effective at conventional thresholds for all patients. These findings seem robust. Cost-effectiveness seems better for some patient subgroups, e.g. especially for patients with good performance status and with advanced disease, where it is estimated the ICER per QALY would be £36,700. Given the relatively small number of patients with mesothelioma, albeit increasing, the overall budget impact of pemetrexed would be unlikely to be more than £5 million per year at present costs.

**Recommendations for further research**

Other agents including anthracyclines and antimetabolites require further evaluation in mesothelioma, in combination with pemetrexed. The use of sequential and also combination chemotherapy should be considered.

The role of supportive care needs to be defined and evaluated. In order to generalise the treatment findings, further studies including patients with poor performance status are needed. Such trials also need to include an assessment of appropriate quality of life data to inform subsequent economic evaluations better.

**Publication**

The Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer-reviewed by a number of independent expert referees before publication in the widely read monograph series *Health Technology Assessment*.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned and funded by the HTA Programme on behalf of NICE as project number 04/17/01. The protocol was agreed in June 2005. The assessment report began editorial review in May 2006 and was accepted for publication in July 2006. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

**Editor-in-Chief:** Professor Tom Walley  
**Series Editors:** Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde, Dr John Powell, Dr Rob Riemsma and Dr Ken Stein  
**Managing Editors:** Sally Bailey and Sarah Llewellyn Lloyd